X4 Pharmaceuticals (XFOR) Accumulated Expenses (2017 - 2025)

X4 Pharmaceuticals (XFOR) has 9 years of Accumulated Expenses data on file, last reported at $18.6 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Expenses fell 19.13% year-over-year to $18.6 million; the trailing twelve-month figure through Dec 2025 stood at $18.6 million (down 19.13% YoY), and the FY2025 full-year result was $18.6 million, down 19.13% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $18.6 million, up from $16.7 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $23.0 million in Q4 2024 and bottomed at $6.9 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $12.7 million (2023), against an average of $13.3 million.
• The widest annual swing landed in 2021, when Accumulated Expenses soared 85.03%; it then sank 35.76% in 2022.
• A 5-year view of Accumulated Expenses shows it stood at $7.9 million in 2021, then surged by 52.91% to $12.0 million in 2022, then rose by 6.5% to $12.8 million in 2023, then soared by 79.5% to $23.0 million in 2024, then fell by 19.13% to $18.6 million in 2025.
• The last three Accumulated Expenses figures came in at $18.6 million (Q4 2025), $16.7 million (Q3 2025), and $13.1 million (Q2 2025), per Business Quant data.

Peer Comparison